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ﬁbrillation
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OHCA = out-of-hospital
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260disorders. They are genetically
heterogeneous and may be char-
acterized by incomplete pene-
trance and variable expressivity
(3,4).
Widely recognized forms of
primary rhythm disorders associ-
ated with SCD in childhood exist,
including the long-QT syndrome
(LQTS) and catecholaminergic
polymorphic ventricular tachycar-
dia (CPVT), both characterized
by speciﬁc electrocardiographic
(ECG) features (5). However, at
times, SCD from ventricular ﬁ-
brillation (VF) may occur in the
absence of recognized ECGfeatures; this is referred to as idiopathic ventricular ﬁbrillation
(IVF). IVF is difﬁcult to track genetically because the affected
status of an individual only becomes apparent following an
arrhythmic event. This limits the number of family members
available for genetic studies, hindering gene discovery with
consequent major implications for genetic testing and risk
stratiﬁcation.
Using an exome sequencing approach, we here identify
a mutation in calmodulin encoded by CALM1 as the caus-
ative genetic defect in a family of Moroccan descent pre-
senting with IVF in childhood and adolescence.
Methods
Clinical data analysis. Clinical data of family members,
including medical records, ECGs, 24-h Holter recordings,
exercise ECGs, and echocardiographic data, were collected
and evaluated. Family members who experienced (aborted)
sudden cardiac arrest were considered affected. The QT
interval was measured using the tangent method (6) and by
averaging 3 consecutive beats in lead II or V5. The QT
interval was corrected for heart rate using Bazett’s formula
(QTc ¼ QT/ORR). QTc duration was considered pro-
longed if it was >450 ms (males) and >460 ms (females).
LQTS scores based on the Schwartz criteria (based on QTc
interval and clinical and family history) were calculated (7,8).
Written informed consent was obtained from all participants
or their guardians. Peripheral blood samples for deoxy-
ribonucleic acid (DNA) isolation were collected from 7
individuals across 2 generations.
Candidate gene analysis. Prior to exome sequencing, exten-
sive candidate gene analysis was carried out for mutations in
genes commonly involved in primary arrhythmia syndromes
and arrhythmogenic cardiomyopathy, including DPP6,
KCNQ1,KCNH2, SCN5A,KCNE1,KCNE2,RYR2,CASQ2,
KCNJ2, TMEM43, JUP, DSG2, TNNT2, and PKP2. These
genes were polymerase chain reaction-ampliﬁed using prim-
ers complementary to ﬂanking intronic sequences, and the
puriﬁed polymerase chain reaction products were Sangersequenced using BigDye Terminator 3.1 chemistry (Applied
Biosystems, Foster City, California).
Exome sequencing. Exome sequencing was carried out
on the proband and his sister, who were both successfully
resuscitated from a cardiac arrest (subjects II-3 and II-6).
Exome sequencing was carried out at the Beijing Geno-
mics Institute (BGI) (Shenzhen, China). In brief, coding
exons were captured from 3 mg of randomly fragmented
genomic DNA using the Agilent SureSelect Human All
Exon kit following the manufacturer’s protocol (Agilent
Technologies, Santa Clara, California). Sequencing was
carried out on a Hiseq2000 sequencer (Illumina, San Diego,
California) for 90-bp paired-end read sequencing to allow
a minimum coverage of 75 fold.
Data analysis. Sequence reads were aligned to the human
reference genome (UCSC NCBI37.1/hg19) using SOAP-
aligner (9) (version 2.21), and functional annotation of high-
quality variants was performed using SOAPsnp software for
the single nucleotide variation. For insertion/deletion
detection, sequence reads were aligned by BWA (10) and
annotated by GATK (11) for break-point identiﬁcation.
The Knime4Bio tool (12) was used to manage and ﬁlter
variants. Synonymous variations that were not located at
splice sites were excluded from further analysis. Heterozy-
gote and homozygote coding and splice site variations of
each sequenced patient were compared with publicly avail-
able variant databases, namely: 1) dbSNP132; 2) Phase 1
version 3 of the 1000 Genomes project (data release October
2012); 3) NHLBI GO Exome Sequencing Project (13); 4)
GoNL (14); 5) the 69 genomes from Complete Genomics;
and 6) an in-house exome database from the BGI. Genetic
variants found in any of these databases were excluded from
further analyses. The 2 exomes were subsequently compared
and genetic variations found in both patients were retained.
Validation and segregation. Variants found in both
exomes were validated and tested for segregation in the fa-
mily by Sanger sequencing on an ABI PRISM 3730 DNA
Sequencer (Applied Biosystems, Foster City, California). A
total of 500 control individuals of Moroccan descent were
tested for the presence of the CALM1 p.F90L variant by
Sanger sequencing.
Results
Clinical data and pedigree. The proband, individual II-3
in the pedigree (Fig. 1A), experienced out-of-hospital
cardiac arrest at age 16 years while romping with a classmate
at school. The initial recorded rhythm was VF that converted
to sinus rhythm after 2 deﬁbrillatory shocks (Fig. 1B). He
underwent comprehensive clinical evaluation, and baseline
testing was unremarkable. Transthoracic echocardiography,
cardiac magnetic resonance imaging, and cardiac catheteri-
zation did not reveal any structural or functional abnor-
malities. His 12-lead ECG showed a sinus rhythm of
74 beats/min, normal conduction intervals, and a QTc
interval of 411 ms. Holter monitoring showed 4 ventricular
I-1 I-2
II-1 II-2 II-3     II-4 II-5 II-6 II-7
SD 9 yr     SD 10 yr
- +                                 +             +               +
- +                                
A B
Aborted VF
II-3 (proband)
1 sec
200 J
C
Rest supine
QTc=434 ms
Peak exercise
QTc= 459 ms
Early recovery
QTc= 464 ms
D
1 sec
ICD recordings (II-6)
II-6 200 J
(Aborted) SCD
Figure 1 Pedigree and Idiopathic VF Phenotype
(A) Pedigree of the family affected by idiopathic ventricular ﬁbrillation (VF). The arrow indicates the proband. Solid symbols indicate (aborted) sudden cardiac death (SCD). Plus
symbol above pedigree symbols indicates carrier of the CALM1 F90L variant; minus symbol indicates wild type. Crossed symbols indicate deceased individuals. Individuals I-2,
II-3, II-6, and II-7 showed a mild increase in QTc interval during exercise. The pedigree has been altered to protect conﬁdentiality. (B) Initial rhythm strip of the proband (II-3) and
his sister (II-6) recorded by the automated external deﬁbrillator. In both cases, the initial rhythm recorded was VF, which was converted to sinus rhythm by deﬁbrillation with 200
J. (C) Resting (supine) and exercise electrocardiograms (ECGs) of the proband II-3. The ECG taken during recovery from exercise shows mild QTc interval prolongation. (D)
Intracardial electrograms retrieved from the implantable cardioverter-deﬁbrillator (ICD) of individual II-6, showing 3 independent VF episodes (each with approximately 2 years in
between). The recordings show the initiation of onset of VF, which is followed by successful deﬁbrillation of the device and subsequent return to sinus rhythm. In all 3 episodes,
mode of onset was not pause dependent, nor was VF initiated by relatively short coupling intervals. Notably, heart rate prior to VF was relatively fast (RR intervals of 378, 390,
and 433 ms, respectively). SD ¼ sudden death.
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261extrasystoles in a 24-h period. Flecainide provocation testing
did not uncover a Brugada ECG pattern. Invasive electro-
physiological testing showed normal sinus node and atrioven-
tricular nodeparameters. Polymorphic ventricular tachycardia
that deteriorated into VF was induced with 3 extrastimuli at
the right ventricular outﬂow tract. On exercise testing, the
proband reached a maximal heart rate of 176 beats/min, and
mild prolongation of the QTc interval was revealed, which
was maximal during early recovery (464 ms) (Fig. 1C). The
patient received an implantable cardioverter-deﬁbrillator
(ICD). During 12 years of follow-up, the patient did not
report any syncopal episodes nor did the ICD record any
episode of (non-)sustained ventricular tachycardia. Genetic
testing was negative for mutations in genes commonly
involved in primary arrhythmia syndromes and arrhythmo-
genic cardiomyopathy.
Just 7 months following the index event of the proband,
his younger sister (II-5) died suddenly at age 10 years.
ECGs taken at 3 and 6 months before her death showed
no abnormalities (QTc ¼ 443 ms, HR ¼ 88 beats/min)(Online Fig. 1). The family history included a sister (II-4)
who died suddenly at the age of 9 years. Another sister (II-6)
collapsed while playing at the playground at the age of 10
years and was successfully resuscitated from VF (Fig. 1B).
Her ECG revealed a normal QTc interval (QTc ¼ 421 ms,
HR ¼ 70 beats/min). She was placed on beta-blocker
therapy, and an ICD was implanted. During a follow-up
of 8 years, she experienced 3 episodes of VF, all of which
were terminated by ICD shocks (Fig. 1D). The youngest
sister (II-7) has thus far been asymptomatic and with an
unremarkable cardiac evaluation. She was implanted with
an ICD at age 7 years, which has not discharged during
a follow-up period of 3 years. Both parents are asympto-
matic and show no ECG abnormalities at rest. However,
upon exercise testing, the mother (I-2) demonstrated pro-
longed QTc intervals at high heart rates (QTc ¼ 476 ms,
HR ¼ 121 beats/min).
None of the individuals displayed signiﬁcant arrhythmias
during 24-h Holter monitoring or exercise testing. All
family members that were tested displayed a maximal heart
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262rate response to exercise. No prominent U waves were ob-
served at rest or during exercise testing. Based on the
Schwartz criteria (7,8), all individuals had a low probability
of having LQTS. Maximal Schwartz scores of 0.5 were
calculated based on the family history of unexplained sud-
den cardiac death below age 30 years.
In summary, the phenotype of this family is characterized
by mild QTc prolongation in the recovery phase after
exercise and idiopathic ventricular ﬁbrillation before the age
of 17 years (Table 1, Online Fig. 2).
Exome sequencing and variant ﬁltering. The presentation
in this family could be compatible with 2 forms of inheri-
tance: either an autosomal recessive pattern or an autosomal
dominant pattern with reduced penetrance. In an attempt to
uncover the underlying genetic cause of sudden cardiac
death in this family, whole-exome sequencing was per-
formed on 2 successfully resuscitated young patients (II-3
and II-6). On average, this yielded more than 85 million
reads per sample, 91% of which could be mapped. The mean
coverage of the target region wasw80-fold, with over 90% of
target regions covered by 10 reads (Online Table 1). Over
27,000 small insertion-deletions and single nucleotide
(including synonymous, missense, nonsense and splice site)
variations were identiﬁed in each of the individuals (Table 2).
IVF is a highly malignant disorder, and underlying
disease-causing variants are under such strong negative
selection that they are unlikely to be detected in public single
nucleotide polymorphism (SNP) or exome databases. We
thus next ﬁltered out genetic variants found in public,
exome and genome databases (dbSNP132, Phase 1 version 3Table 1 Clinical Characteristics of the Family
I-1 I-2 II-1 II
Sex M F
SCD (age, yrs)
VF (age ﬁrst event, yrs)
Schwartz score 0.5 0.5 NA 0
Age at ECG, yrs 41 45 NA 2
Resting QT (ms) 400 360 NA 33
Resting heart rate (beats/min) 67 78 NA 8
Resting QTc (ms) 423 410 NA 39
Age at exercise ECG NA 57 NA 2
Peak exercise
QT (ms) NA 265 NA 22
HR (beats/min) NA 151 NA 19
QTc (ms) NA 420 NA 40
Early recovery*
QT (ms) NA 335 NA 26
HR (beats/min) NA 121 NA 14
QTc (ms) NA 476 NA 41
Late recoveryy
QT (ms) NA 365 NA 30
HR (beats/min) NA 92 NA 10
QTc (ms) NA 452 NA 41
ICD (implanted at age, yrs)
Schwartz scores 1 indicate low probability for long-QT syndrome. *Early recovery indicates 1 min of re
ECG ¼ electrocardiogram; HR ¼ heart rate; ICD ¼ implantable cardioverter-deﬁbrillator; QTc ¼ correcof the 1000 Genomes project, exome variant server, GoNL,
the 69 genomes from Complete Genomics, and an in-house
exome database from BGI). This identiﬁed 397 and 367
novel variations in the 2 successfully resuscitated young
patients: II-3 and II-6, respectively (Table 2).We next looked
for the variants that the 2 individuals shared, and we kept the
66 heterozygous variants in 66 different genes that they
shared. No variants were shared homozygously among the
2 individuals, which might have been compatible with an
autosomal recessive model of inheritance.
Validation and segregation of candidate variants. Of the
66 variants shared between the 2 resuscitated patients (II-3
and II-6), 11 variants were excluded as they occurred in
pseudogenes or were mapped to regions that are duplicated
in the genome and, therefore, also likely involve pseudo-
genes. The remaining 55 variants were validated by Sanger
sequencing (primers are available upon request). Of these,
only 9 variants were also carried by the sibling who died
suddenly (II-5) as well as by the mother (I-2). We next
investigated the 9 genes harboring these variants for
a potential role in cardiac function by conducting a literature
search (assessing expression data, insight into function and
involvement in disease) and by noting the presence among
the 4,054 genes comprising the Cardiovascular Gene
Ontology Annotation Initiative gene list (15) (Table 3).
This allowed us to exclude 6 genes that have been previously
related to a noncardiac disease/phenotype (AIRE [16,17],
CIAPIN1 [18], C10orf112/AD7 [19–21], SEMA5A [22–24],
TTC3 [25] and ZNF764 [26]). Of note, the nucleotides
affected by these 6 variants also displayed low genomic-2 II-3 II-4 II-5 II-6 II-7
F M F F F F
Y (9) Y (10)
Y (16) Y (10)
.5 0.5 NA 0.5 0.5 0.5
3 27 NA 9 18 9
4 371 NA 372 380 320
3 82 NA 88 77 104
2 434 NA 449 430 421
3 28 NA NA 19 10
5 268 NA NA 268 245
1 176 NA NA 169 182
1 459 NA NA 450 428
3 284 NA NA 291 282
9 160 NA NA 159 162
4 464 NA NA 474 463
8 320 NA NA 316 311
8 118 NA NA 129 131
3 447 NA NA 464 460
Y (16) Y (10) Y (7)
covery; ylate recovery indicates 4 min of recovery.
ted QT interval; SCD ¼ sudden cardiac death; VF ¼ ventricular ﬁbrillation.
Table 2 Summary of Variant Filtering
II-3 II-6
Coding single-nucleotide variants
(exons, exon boundaries, splicing)
27,958 28,001
Homozygous 9,171 9,090
Heterozygous 18,787 18,911
Synonymous variants ﬁltered out 17,285 17,290
Novel variants 397 367
Homozygous 5 6
Heterozygous 392 361
Shared variants by the 2 patients 66
Homozygous 0
Heterozygous 66
Not in duplicated regions or in pseudogenes 55
Carried by II-5 and I-2 9
Variants in genes not involved in other phenotypes 3
Carried by II-7 and not by II-2 1
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263evolutionary rate proﬁling scores (27) (Table 3), indicating
low evolutionary conservation.
Of the remaining 3 variants (in CALM1 [28,29], CLTC
[30], and ZFYVE9 [31]; in fact the only 3 genes of the
original 66 shared variants that are listed in the Cardiovas-
cular Gene Ontology Annotation Initiative gene list), only
1 variant, in the CALM1 gene, was also inherited by the
youngest sister (II-7), who displayed borderline QTc in-
terval prolongation during exercise, and was not inherited by
individual II-2. Notably, the genomic position affected by
the CALM1 variant displays high evolutionary conservation,
supporting its importance (32). In addition, the amino acid
residue affected by the mutation (phenylalanine at position
90 (F90)) is highly conserved throughout evolution (from
yeast to mammals) (Figs. 2A and 2B). Finally, we excluded
the presence of the CALM1 variant in 500 control indi-
viduals of Moroccan descent.Ta
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IVF, a rare rhythm disorder, is characterized by VF in the
absence of ECG abnormalities or structural heart disease is
characterized by VF in the absence of ECG abnormalities or
structural heart disease. Due to this elusive clinical presen-
tation, the disorder is difﬁcult to track genetically. To date,
only 1 haplotype encompassing the DPP6 gene showed
evidence for strong genetic linkage to the disease (33). Using
whole-exome sequencing, we have, for the ﬁrst time, linked
a mutation in CALM1 to IVF presenting in childhood and
adolescence.
CALM1 encodes calmodulin (CaM), a ubiquitously
expressed, evolutionarily conserved protein that is an
essential regulator of calcium-dependent processes in virtu-
ally every cell type (34). Two other genes (CALM2 and
CALM3), each located on different chromosomes, encode
CaM. Although the coding regions differ to some extent, as
do the regulatory ﬂanking noncoding regions, the protein
product of these 3 genes is identical.
Figure 2 The CALM1 F90L Mutation
(A) Partial sequence electropherograms showing the CALM1 c.268T>C variant in an affected family member (II-3) and an unaffected family member (II-2). (B) Multiple protein
sequence alignment shows conservation of CaM F90 residues throughout evolution (from yeast to mammals). (C) Calmodulin protein sequence. The EF-hand motifs (EF 1-4) are
underlined and the highly conserved phenylalanines (F) are indicated in red. The p.F90L variant associated with idiopathic ventricular ﬁbrillation (IVF) is circled in red. Calmodulin
mutations previously identiﬁed linked to catecholaminergic polymorphic ventricular tachycardia (CPVT) (28) are indicated in green, mutations previously linked to long-QT
syndrome (LQTS) in infancy (29) are indicated in blue.
Marsman et al. JACC Vol. 63, No. 3, 2014
A CALM1 Mutation in IVF in Childhood January 28, 2014:259–66
264Mutations in CALM1 and CALM2 have recently been
linked to 2 other primary rhythm disorders (28,29). In 1
study, Nyegaard et al. (28) linked mutations (N53I and
N97S) in CALM1 with early onset CPVT. In another study,
Crotti et al. (29) identiﬁed 3 de novo mutations in CALM1
(D130G and F142L) and CALM2 (D96V) in 4 infants
presenting with severe ventricular arrhythmias and markedly
prolonged QTc intervals (>600 ms) in the ﬁrst year of life
(29). A number of features distinguish the clinical presen-
tation in the family we studied from patients of these 2
studies. First, the CALM1 mutation carriers in our study
displayed no bidirectional or polymorphic ventricular ta-
chycardia during repeated exercise tests. Furthermore, their
QTc intervals were normal at baseline and only became
mildly prolonged with exercise. Second, in the family we
studied, events to date occurred between 9 and 16 years of
age. Finally, the patients studied by Crotti et al. (29)
exhibited neurodevelopmental delay, whereas the patients
in our study did not present with such disabilities. When
considered in the light of these 2 previous studies, our
ﬁndings point to the occurrence of a broad spectrum of
cardiac rhythm disease that could arise from mutations in
genes encoding CaM.
CaM is a cytoplasmic molecule that can bind 4 calcium
ions with high afﬁnity at its EF-hand motifs and subse-
quently interact with target proteins. In the heart, CaM
binds and regulates a number of ion channels and their
regulators (35). Disruption of these interactions may lead todisturbances in several processes, including excitability,
excitation-contraction coupling, and refractoriness, which
may cause arrhythmia. Indeed, mutations affecting CaM-
binding sites (termed “IQ domains”) in ion channels have
long been associated with inherited arrhythmia disorders.
For instance, mutations in the IQ domain of Kv7.1 (encoded
by KCNQ1), Cav1.2 (CACNA1C), and Nav1.5 (SCN5A)
have been shown to affect CaM binding and thereby affect
the function of these channels to cause disease (36–39).
Dysregulated binding of CaM to ion channels can have dif-
ferent consequences on ion channel function. These include
altered calcium-sensitive gating, channel assembly, and cell
surface expression (36,40,41).
CALM mutations linked thus far to CPVT or LQTS
in infancy predominantly affect residues within the EF-
hand domains of the protein and have been shown to
affect the binding of calcium in studies conducted in vitro
(28,29). In addition, abnormal interaction of CaM with
the ryanodine receptor was described for the CALM1-
N97S linked to CPVT. The mutation causing IVF in the
family we describe is located between 2 EF domains,
namely, EF-2 and -3 (Fig. 2C). This inter-EF hand linker
contains 3 highly-conserved aromatic phenylalanine resi-
dues and is important for positioning the EF hands
for high-afﬁnity cooperative calcium binding (42,43).
The mutation in our IVF family causes the substitution of
1 of these phenylalanines at position 90 for leucine. Of
note, all 8 phenylalanines residues in CaM are highly
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and structural studies have uncovered a crucial role of each
of these phenylalanines residues, including F90, in medi-
ating direct interaction of CaM with target peptides
(44,45). Although this requires further studies, one could
speculate that mutations in CaM cause disease through
different mechanisms that could occur through effects on
calcium binding and/or binding of target proteins.
All 3 CaM genes are expressed in the human fetal, infant,
and adult left ventricle (29). However, differences in the
relative expression of the CaM product arising from the 3
respective genes may occur across the different compart-
ments in the heart. Interestingly, the CALM1 messenger
ribonucleic acid transcript was found to be more abundant in
Purkinje ﬁbers as compared to the working atrial and
ventricular myocardium in the nondiseased human heart
(46). This raises the intriguing possibility that the CALM1
F90L defect is more pronounced in the Purkinje system.
Of note, the mother (I-2) displayed mild exercise-induced
QTc prolongation but has remained asymptomatic. This
points to a role for other, possibly genetic, factors in
modulation of the arrhythmia risk (47). The mild exercise-
induced QTc prolongation is also found among the 2
siblings who were resuscitated. Although none of the family
members met with the diagnostic criteria for LQTS (7,8),
because ECG recordings are not available in a large number
of mutation carriers in this family, it is difﬁcult to rule out
LQTS with certainty. Nevertheless, the occurrence of VF in
4 siblings from this family highlights the importance of the
discovery of this variant in pre-symptomatic genetic diag-
nosis to guide therapy.
Study limitations. In this study we did not carry out
functional studies on the CALM1 F90L mutant. Such
studies will be necessary to provide insight into the mech-
anism by which this mutation leads to the particular clinical
presentation in this family.
Conclusions
Our results suggest that the CALM1 F90L mutation,
identiﬁed by exome sequencing, is causal to VF and SCD in
childhood and adolescence. This study highlights the fact
that exome sequencing is a powerful and efﬁcient way to
drastically reduce the number of candidate genes, even in
a family with a small number of deﬁnitely affected
individuals.
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